Fucoxanthin as a Geroprotector: Experimental Data on Mice
Open Access
- 18 August 2026
- journal article
- Published by Ural State Medical University in Ural Medical Journal
- Vol. 25 (4) , 108-120
Abstract
Introduction . Th e search for compounds capable of modulating key mechanisms of aging remains one of the pressing challenges of modern medicine. Fucoxanthin, a carotenoid derived from brown algae, possesses antioxidant and anti-infl ammatory properties; however, its eff ects on complex biomarkers of aging in mammals remain insuffi ciently studied. Objective is to comprehensively evaluate the eff ects of long-term oral administration of fucoxanthin on biomarkers of aging, including pro-infl ammatory cytokines, advanced glycation end products, and metabolic parameters in aging mice. Materials and methods . Th e study included 30 male ICR/CD1 mice divided into three groups: 1) mature controls (10 months), 2) aged controls (18 months), and 3) aged mice receiving fucoxanthin (18 months) at a dose of 20 mg/kg body weight per day for 8 months. Serum levels of IL-6, TNF-α, MCP-1, and AGEs, as well as biochemical parameters, were assessed. Results . In aged control mice, all measured markers were signifi cantly higher than in mature controls. Fucoxanthin administration contributed to a reduction in IL-6, TNF-α, MCP-1, and AGEs levels, along with an improvement in the metabolic profi le (decreased glucose, triglycerides, ALT and AST activities, and increased HDL cholesterol and albumin). Conclusion . Th e obtained results demonstrate a comprehensive geroprotective eff ect of fucoxanthin, refl ected in suppression of the senescence-associated secretory phenotype, reduction of carbonyl stress, and improvement of metabolic status. Th ese fi ndings support the potential of fucoxanthin as a promising geroprotector for further research in the prevention of age-associated diseases.Keywords
This publication has 26 references indexed in Scilit:
- Dietary advanced glycation end products (AGEs): A modifiable risk factor in the prevention of chronic diseases associated with aging?Biochimie, 2025
- Senescent cell depletion alleviates obesity-related metabolic and cardiac disordersMolecular Metabolism, 2024
- Fisetin as a senotherapeutic agent: Evidence and perspectives for age-related diseasesMechanisms of Ageing and Development, 2024
- Findings from the Global Burden of Disease Study 2021The Lancet, 2024
- The senescence-associated secretory phenotype and its physiological and pathological implicationsNature Reviews Molecular Cell Biology, 2024
- Fucoxanthin diminishes oxidative stress damage in human placenta-derived mesenchymal stem cells through the PI3K/Akt/Nrf-2 pathwayScientific Reports, 2023
- Chronic inflammation and the hallmarks of agingMolecular Metabolism, 2023
- Multiple roles of fucoxanthin and astaxanthin against Alzheimer's disease: Their pharmacological potential and therapeutic insightsBrain Research Bulletin, 2022
- The landscape of agingScience China Life Sciences, 2022
- Fucoxanthin increases lifespan of Drosophila melanogaster and Caenorhabditis elegansPharmacological Research, 2015